Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of May 21, 2026, VRDN trades at $17.55 with a market cap of $1.78B and a P/E ratio of 0.00. VRDN moved +10.36% today. Year to date, VRDN is -41.62%; over the trailing twelve months it is +27.57%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $32.08. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Viridian Therapeutics Shares Surge 35.6% After REVEAL-2 Phase III TED Success: Viridian Therapeutics announced Phase III REVEAL-2 trial in 204 TED patients met primary endpoints with proptosis responder rates of 50% and 54% in four-weekly and eight-weekly cohorts versus 15% for placebo. The stock jumped 35.6% to open at $19.07 following data release that coincided with the Q1 earnings report.
| Metric | Value |
|---|---|
| Price | $17.55 |
| Market Cap | $1.78B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.29 |
| 52-Week Low | $9.90 |
| Volume | 44 |
| Avg Volume | 0 |
| Revenue (TTM) | $70.85M |
| Net Income | $-342.60M |
| Gross Margin | 0.00% |
14 analysts cover VRDN: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.08.